On Nov 06, major Wall Street analysts update their ratings for $Vertex Pharmaceuticals (VRTX.US)$, with price targets ranging from $486 to $600.
J.P. Morgan analyst Jessica Fye maintains with a buy rating, and sets the target price at $503.
Barclays analyst Gena Wang maintains with a hold rating, and maintains the target price at $509.
Evercore analyst Liisa Bayko maintains with a buy rating, and maintains the target price at $515.
TD Cowen analyst Phil Nadeau maintains with a buy rating, and maintains the target price at $525.
Oppenheimer analyst Hartaj Singh maintains with a buy rating, and adjusts the target price from $500 to $540.
Furthermore, according to the comprehensive report, the opinions of $Vertex Pharmaceuticals (VRTX.US)$'s main analysts recently are as follows:
Following Vertex Pharmaceuticals' third-quarter results surpassing consensus and an approximate 1% raise in 2024 revenue guidance at the midpoint, expectations are now set on the forthcoming suzetrigine Phase 2 lumbosacral radiculopathy (LSR) data anticipated by year-end.
The company's strong performance in its cystic fibrosis business demonstrates the ongoing robustness of its primary operations, which is expected to sustain the stock's high valuation. However, the outlook leading into FY25 may present more challenges compared to FY24, with potential data on suzetregine anticipated to confirm efficacy but perhaps not generate significant enthusiasm, and the launches of acute pain treatments and Casgevy possibly experiencing gradual uptake.
Here are the latest investment ratings and price targets for $Vertex Pharmaceuticals (VRTX.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月6日，多家华尔街大行更新了$福泰制药 (VRTX.US)$的评级，目标价介于486美元至600美元。
摩根大通分析师Jessica Fye维持买入评级，目标价503美元。
巴克莱银行分析师Gena Wang维持持有评级，维持目标价509美元。
Evercore分析师Liisa Bayko维持买入评级，维持目标价515美元。
TD Cowen分析师Phil Nadeau维持买入评级，维持目标价525美元。
奥本海默控股分析师Hartaj Singh维持买入评级，并将目标价从500美元上调至540美元。
此外，综合报道，$福泰制药 (VRTX.US)$近期主要分析师观点如下：
福泰制药第三季度业绩超出共识，营业收入2024年中点预期上调约1%，目前市场期待即将公布的suzetrigine第2期腰骶神经根病（LSR）数据。
公司在囊性纤维化业务中的强劲表现展示了其主营业务的持续强劲性，预计将支撑该股票的高估值。然而，进入2025财年的前景可能会比2024财年面临更多挑战，suzetrigine的潜在数据有望证实疗效，但可能不会带来明显热情，急性疼痛治疗和Casgevy的推出可能会逐渐受到接受。
以下为今日8位分析师对$福泰制药 (VRTX.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
